Literature DB >> 2530253

Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients.

A S Boyd1, A Menter.   

Abstract

Erythroderma represents the most severe form of psoriasis. In addition to its morbidity and severe discomfort, erythrodermic psoriasis also may be potentially life-threatening. We present demographic, clinical, and laboratory findings of 50 patients with psoriatic erythroderma seen at our day-care center during a 9 1/2-year period. Precipitating factors included administration of systemic corticosteroids and the excessive use of topical steroids, phototherapy complications, severe emotional stress, and preceding illness. Treatment options are discussed on the basis of an average follow-up period of 34 months. There appears to be a certain subgroup of patients with highly unstable psoriasis for whom appropriately planned therapeutic regimens are essential.

Entities:  

Mesh:

Year:  1989        PMID: 2530253

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  15 in total

1.  Martin Alan Menter, MD: a conversation with the editor. Interview by William Clifford Roberts.

Authors:  Martin Alan Menter
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-04

2.  Erythrodermic Psoriasis and Staph-Infective Endocarditis-A Conundrum in Succession.

Authors:  Arti Patel; Frederick Venter; Kulraj Grewal; Rupam Sharma; Greti Petersen; Arash Heidari
Journal:  J Investig Med High Impact Case Rep       Date:  2022 Jan-Dec

3.  Erythrodermic psoriasis secondary to systemic corticosteroids.

Authors:  Matthew Heinrich; Elizabeth Cook; Jenna Roach; Rita Medrano Juarez; Drew Payne; Randy Atkins; Cloyce Stetson
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-11-11

4.  IL-17 Responses Are the Dominant Inflammatory Signal Linking Inverse, Erythrodermic, and Chronic Plaque Psoriasis.

Authors:  Xianying Xing; Yun Liang; Mrinal K Sarkar; Liza Wolterink; William R Swindell; John J Voorhees; Paul W Harms; Joanne M Kahlenberg; Andrew Johnston; Johann E Gudjonsson
Journal:  J Invest Dermatol       Date:  2016-07-21       Impact factor: 8.551

Review 5.  Psoriasis.

Authors:  Paola Di Meglio; Federica Villanova; Frank O Nestle
Journal:  Cold Spring Harb Perspect Med       Date:  2014-08-01       Impact factor: 6.915

6.  Clinical Features and Genetic Polymorphism in Chinese Patients with Erythrodermic Psoriasis in a Single Dermatologic Clinic.

Authors:  Yang Lo; Hsien-Yi Chiu; Tsen-Fang Tsai
Journal:  Mol Diagn Ther       Date:  2020-02       Impact factor: 4.074

7.  Erythrodermic Psoriasis Treated with Golimumab: A Case Report.

Authors:  Won-Ku Lee; Gun-Wook Kim; Hyun-Ho Cho; Won-Jeong Kim; Je-Ho Mun; Margaret Song; Hoon-Soo Kim; Hyun-Chang Ko; Moon-Bum Kim; Byung-Soo Kim
Journal:  Ann Dermatol       Date:  2015-07-29       Impact factor: 1.444

8.  Effectiveness of conventional drug therapy of plaque psoriasis in the context of consensus guidelines: a prospective observational study in 150 patients.

Authors:  Ashok Kumar Gupta; Shyam Sunder Pandey; Bajrangprasad Laxminarayan Pandey
Journal:  Ann Dermatol       Date:  2013-05-10       Impact factor: 1.444

9.  Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: a report of two cases.

Authors:  Rosita Saraceno; Marina Talamonti; Marco Galluzzo; Andrea Chiricozzi; Antonio Costanzo; Sergio Chimenti
Journal:  Case Rep Dermatol       Date:  2013-09-26

10.  Erythrodermic psoriasis: pathophysiology and current treatment perspectives.

Authors:  Rasnik K Singh; Kristina M Lee; Derya Ucmak; Merrick Brodsky; Zaza Atanelov; Benjamin Farahnik; Michael Abrouk; Mio Nakamura; Tian Hao Zhu; Wilson Liao
Journal:  Psoriasis (Auckl)       Date:  2016-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.